Shandong Fangtansi Biopharmaceutical

Shandong Fangtansi Biopharmaceutical is a clinical-stage biotechnology company headquartered in Jinan, China, focused on the discovery and development of innovative small molecule drugs. The company's primary research efforts are directed toward oncology and metabolic diseases, aiming to provide effective treatments for patients with significant unmet medical needs. Its lead candidate, FTS-001, is a highly selective CDK4/6 inhibitor currently in Phase 2 clinical trials for the treatment of advanced breast cancer. Fangtansi maintains a robust internal R&D platform and is expanding its pipeline with several early-stage programs targeting various oncogenic pathways. The company is recognized as a key player in the regional life sciences sector within the Shandong province.